Keith Hoffmaster
Overview
Explore the profile of Keith Hoffmaster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheung A, Hurley B, Kerrigan R, Shu L, Chin D, Shen Y, et al.
J Med Chem
. 2018 Nov;
61(24):11021-11036.
PMID: 30407821
Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause of death in infants and toddlers. SMA is caused by the deletion or a loss of function...
2.
LItalien L, Orozco O, Abrams T, Cantagallo L, Connor A, Desai J, et al.
Clin Cancer Res
. 2018 Apr;
24(14):3465-3474.
PMID: 29615457
Hypersensitivity reactions (HSRs) were observed in three patients dosed in a phase I clinical trial treated with LOP628, a KIT targeted antibody drug conjugate. Mast cell degranulation was implicated as...
3.
Dardaei L, Wang H, Singh M, Fordjour P, Shaw K, Yoda S, et al.
Nat Med
. 2018 Mar;
24(4):512-517.
PMID: 29505033
Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors,...
4.
Tuntland T, Ethell B, Kosaka T, Blasco F, Zang R, Jain M, et al.
Front Pharmacol
. 2014 Aug;
5:174.
PMID: 25120485
Characterizing the relationship between the pharmacokinetics (PK, concentration vs. time) and pharmacodynamics (PD, effect vs. time) is an important tool in the discovery and development of new drugs in the...
5.
Barnes-Seeman D, Boiselle C, Capacci-Daniel C, Chopra R, Hoffmaster K, Jones C, et al.
Bioorg Med Chem Lett
. 2014 Jul;
24(16):3979-85.
PMID: 24986660
Herein we report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors. Optimizing potency in...
6.
Kablaoui N, Patel S, Shao J, Demian D, Hoffmaster K, Berlioz F, et al.
Bioorg Med Chem Lett
. 2012 Dec;
23(3):907-11.
PMID: 23266122
A novel series of potent benzoxazole mPGES-1 inhibitors has been derived from a hit from a high throughput screen. Compound 37 displays mPGES-1 inhibition in an enzyme assay (0.018 μM)...
7.
Wang Q, Bushell S, Qing M, Xu H, Bonavia A, Nunes S, et al.
J Virol
. 2011 Apr;
85(13):6548-56.
PMID: 21507975
Viral replication relies on the host to supply nucleosides. Host enzymes involved in nucleoside biosynthesis are potential targets for antiviral development. Ribavirin (a known antiviral drug) is such an inhibitor...
8.
Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, Radetich B, et al.
Proc Natl Acad Sci U S A
. 2011 Apr;
108(17):6739-44.
PMID: 21502533
The search for novel therapeutic interventions for viral disease is a challenging pursuit, hallmarked by the paucity of antiviral agents currently prescribed. Targeting of viral proteins has the inextricable challenge...
9.
Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach R, et al.
Expert Opin Drug Metab Toxicol
. 2009 Jul;
5(10):1159-74.
PMID: 19637986
Assessment of drug-liver interactions is an integral part of predicting the safety profile of new drugs. Existing model systems range from in vitro cell culture models to FDA-mandated animal tests....